Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
They also used up some of the prior shelf.
It's easy to lose money on a fake long position.
Volume has almost completely dried up. The algos are showing a diminishing return because there are no "real" shares available to try to steal in this range. It's been largely daytraders competing with each other. Now what? Refuse to allow it to run but can't shakeout by shorting anymore either, or induce short selling, so the most they can do is keep it below technical levels. A conundrum. So we just sit here treading water.
100 share trades constitute big blocks to these algo traders. Typical trade is more like 39 shares. lol
AZN needs to bolster its pipeline big time. And it has a huge hoard of cash to do it with.
Gold, it's not clear why Sectoral even filed a 13G with only 1.8% of outstanding shares. A mystery.
Since you bring that up, Hovacre, the favorable ADXS GOG data comparison to Avastin is actually understated because the GOG subject patients had extremely advanced disease. I understand it was not a direct comparison study, but ADXS's numbers were so favorable in an indirect comparison that its superiority seems highly likely. Not to mention the favorable safety profile.
Oak, today's short data actually shows it down another couple of hundred k shares from that number.
I think you're right, Blue. ADRO sold away alot of its equity in the indications, and its stock benefited. However, the flip side of the coin is that ADXS has retained its equity thus far, which actually increases it long term intrinsic value, not diminishes it. This highlights the short-sighted mentality of the market. But now ADXS is in a great position to cash in big time, because it will get top dollar for licenses.
Sure, I totally agree that DOC should be greedy and demand proper value for a licensing deal for AXAL, which value is BIG. What I meant is that he should not try to wait too long to do it. There is plenty of value there right now, so take it. Validate the entire platform and take future dilution out of play. We have plenty of additional indications to monetize later. Take the sure thing now, partially de-risk, and let it all play out.
I guess I'll never understand why you think anyone cares that management gives itself stock options, etc., and why that would cause a ridiculously-low valuation. It may be unfair but it has no material effect on the value of the company. It's a relative pittance, and not exactly abnormal in corporate America. We'll have to agree to disagree. The only issue, in my opinion, that could be having some negative effect--although not to the extent that it makes the current valuation remotely accurate--is the lack of a "real" BP deal for a more advanced product, such as AXAL. If I had to fault management for anything it would be that. NEO was a great deal, but its development is in very early stages. Although the longer they wait on AXAL, prostate, head and neck etc., the more lucrative. That is the trade off. But it is time. They should not get too greedy, particularly with the distinct possibility of fast movement in the EU approval process.
With all due respect, FBG, the clinical development program IS the business plan. The share price is the result of a concerted manipulation scheme enabled by a still weak biotech market, and nothing else.
Looks like the robots took a snow day. A very nice blizzard in progress.
No worries. Thanks for keeping an eye out.
Wait, how many shares did Amgen buy in August?
Is there any reason that patients cannot have already had chemo/radiation by the time that they show up at ADXS's door? Seems like an odd process. "Go try chemo for a few months, which probably won't work. Maybe then we will give you something that does actually work."
Sure thing, Dawson. There are virtually no "investor" shares trading hands. It is nearly all just daytraders trying to scalp .25 every day and algorithms trading the same shares back and forth to each other.
All part of the plan, Maple. The intent is to bore you out of your shares, which is why they have it suppressed and trapped in a range.
I'm with you, Xena. All true.
When you say "MACD shows how they were holding it down" you mean disguised accumulation/covering, I assume.
If his stock is restricted then he still owns it, which negates the premise of your question of "why would he leave just when he's supposedly about to get rich?" You should really try to make more sense with your manipulation attempts, OB. Your employer is not getting its money's worth.
Well, breaking through the 9.40 range would have been better, but ... If you're a trader. Doesn't matter much to us investors either way.
They prevented the pps from breaking through the moving average and so traders are bringing it down.
You got it, Blue. The action in the indexes and in ADXS sure looks like carefully engineered, orderly covering. When they are done, there we go.
Mastiff, clearly North America and Europe are huge markets. Europe in particular is attractive to BPs due to the fast-moving EU approval progress. There may be less people in the U.S. and Asia, but they have money to spend. The rights to Canada were definitely licensed as part of the Knight deal.
How has ADXS given away rights to largest markets for cervical cancer? There is no deal for the U.S., Europe, etc. I have no clue what is the status of rights for Asian markets, due to the mystery of Biocon. Anyone?
DOC should be fired for causing this horrible development of dosing the first patient withOUT also arranging for the pps to take off in response. He should have instructed his secret band of shady traders to run the stock up on the news, using HFT and spam e-mails.
Interesting report on the genomic lung cancer therapy. NEO could be the fledgling phase of a technology that could actually be called a "cure" at some point. Exciting times. Btw, a large percentage of my posts get deleted. Some I cannot even figure out why.
Husker, that has been my prediction all along. My money is on Amgen. NEO is so perfectly in Amgen's wheelhouse, and they really need the rights to the base indications as well. ADXS will eventually be part of Amgen. And Amgen may buy the whole thing sooner than anyone expects, because it will not risk losing indications to other BPs. It will want/need the whole enchilada.
MM's engineering a consolidation.
Understood, Fbg. ADXS will probably never develop a distribution arm. When I said "go it alone" I really meant "remain an independent company," i.e., "not agree to a buyout." Although Although ADXS could theoretically remain independent and continue running R&D and manufacturing, with licensing deals for marketing and distribution.
DOC will take the money and run when it is offered. If ADXS goes it alone after approval his money will remain largely locked up.
I almost forgot about Chinaman. He was a good guy too, quite a character, and he definitely had a bit of a trader mentality, so I can see him just moving on, as you say. 2017 will be a good year. I think the short suppressors are just looking for the right catalyst and then they will change their tune and this thing will roll. They are already soft-preparing for it, it seems.
J&E was, unfortunately, driven away from the other board I frequented, by shorts and fake longs who correctly viewed his stellar positive analysis as a threat to their interests.
J&E is an ace. I'm sorry he/she is no longer around.
Absolutely, Fb. It's not a matter of "if," it's a matter of "when." And the same parties who have been shorting and suppressing will use their nefarious methods in the opposite direction. Personally, I think they have already begun, slowly but surely.
FBG, the mm's obviously are dealers, buying and selling at the same time, with a spread. When they deal from the shorts side they are not maintaining any inventory of shares to sell to buyers. They are fulfilling demand for shares by shorting them to the buyers. Thus, they maintain a large short position which, of course, means that they don't want to see the market rise too much because then they could get stuck. So they are suppressing the pps. But they can't let their short position grow too large, so they periodically cover some when the price gets low enough. Then when the pps rises they repeat the cycle. That is why they have us trapped in a fairly well-defined range.
When the mm's stop dealing from the short side, that's when this thing will really reverse.
Lowest short interest since July. Nice.
I figured. Thanks, Phyto.